Héctor Vaquera, Research trainee at Hematology Department of UANL, shared a post on X:
“New publication
Here we synthethized available evidence on the use of low-doses of nivolumab for r/r HL, an alternative not-so-rarely used in LMICs.”
Title: Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Systematic Review
Authors: Héctor A. Vaquera-Alfaro, José Emiliano Montelongo-Cepeda, Antonio Vega-Mateos, Anahí Morales-Pedraza, Haydeé Verduzco-Aguirre, David Gómez Almaguer, Luis Villela, Perla R. Colunga-Pedraza
You can read the Full Article on JCO Global Oncology.
More posts featuring Héctor Vaquera.